Are there differences in lipid peroxidation and immune biomarkers between major depression and bipolar disorder: Effects of melancholia, atypical depression, severity of illness, episode number, suicidal ideation and prior suicide attempts

Progress in Neuro-Psychopharmacology and Biological Psychiatry

Volumn 81, Issue , 2018, Pages 372-383

  Sowa Kućma, Magdalena ^a,b   Styczeń, Krzysztof ^c   Siwek, Marcin ^c   Misztak, Paulina ^a,c   Nowak, Rafał J ^c   Dudek, Dominika ^c   Rybakowski, Janusz K ^d   Nowak, Gabriel ^a,c   Maes, Michael ^e,f,g,h  

^a POLISH ACADEMY OF SCIENCES   (Poland)

^b UNIVERSITY OF RZESZÓW   (Poland)

^c JAGIELLONIAN UNIVERSITY MEDICAL COLLEGE   (Poland)

^d POZNAN UNIVERSITY OF MEDICAL SCIENCES   (Poland)

^e CHULALONGKORN UNIVERSITY   (Thailand)

^f DEAKIN UNIVERSITY   (Australia)

^g MEDICAL UNIVERSITY OF PLOVDIV   (Bulgaria)

^h Revitalis   (Netherlands)

Author keywords

Bipolar disorder; Cytokines; Immune; Major depression; Melancholia; Oxidative stress

Indexed keywords

BIOLOGICAL MARKER; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; INTERLEUKIN RECEPTOR; SOLUBLE INTERLEUKIN 1 RECEPTOR ANTAGONIST; SOLUBLE INTERLEUKIN 2 RECEPTOR; SOLUBLE INTERLEUKIN 6 RECEPTOR; SOLUBLE TUMOR NECROSIS FACTOR RECEPTOR 60; SOLUBLE TUMOR NECROSIS FACTOR RECEPTOR 80; THIOBARBITURIC ACID REACTIVE SUBSTANCE; TUMOR NECROSIS FACTOR RECEPTOR; UNCLASSIFIED DRUG; IL6 PROTEIN, HUMAN; INTERLEUKIN 6;

ADULT; AGED; ARTICLE; ATYPICAL DEPRESSION; BIPOLAR DISORDER; BLOOD LEVEL; CASE CONTROL STUDY; CELLULAR IMMUNITY; CONTROLLED STUDY; DISEASE SEVERITY; FEMALE; HUMAN; LIPID PEROXIDATION; MAJOR CLINICAL STUDY; MAJOR DEPRESSION; MALE; MELANCHOLIA; OXIDATIVE STRESS; SIGNAL TRANSDUCTION; SUICIDAL IDEATION; SUICIDE ATTEMPT; BLOOD; COMPARATIVE STUDY; HOSPITALIZATION; IMMUNOLOGY; METABOLISM; MIDDLE AGED; PHYSIOLOGY; PSYCHOLOGICAL RATING SCALE; PSYCHOLOGY; SEVERITY OF ILLNESS INDEX; YOUNG ADULT;

ADULT; AGED; BIOMARKERS; BIPOLAR DISORDER; CASE-CONTROL STUDIES; DEPRESSIVE DISORDER, MAJOR; FEMALE; HOSPITALIZATION; HUMANS; INTERLEUKIN-6; LIPID PEROXIDATION; MALE; MIDDLE AGED; PSYCHIATRIC STATUS RATING SCALES; SEVERITY OF ILLNESS INDEX; SUICIDAL IDEATION; SUICIDE, ATTEMPTED; THIOBARBITURIC ACID REACTIVE SUBSTANCES; YOUNG ADULT;

EID: 85029219052     PISSN: 02785846     EISSN: 18784216     Source Type: Journal    
DOI: 10.1016/j.pnpbp.2017.08.024     Document Type: Article

References (104)

1. Akiskal, H.S., Validating ‘hard’ and ‘soft’ phenotypes within the bipolar spectrum: continuity or discontinuity?. J. Affect. Disord. 73:1–2 (2003), 1–5.
2. American Psychiatric Association, Desk Reference to the Diagnostic Criteria from DSM-IV-TR. 2000, American Psychiatric Association, Arlington VA.
3. Andreazza, A.C., Kauer-Sant'anna, M., Frey, B.N., Bond, D.J., Kapczinski, F., Young, L.T., Yatham, L.N., Oxidative stress markers in bipolar disorder: a meta-analysis. J. Affect. Disord. 111:2–3 (2008), 135–144.
4. Arend, W.P., Guthridge, C.J., Biological role of interleukin 1 receptor antagonist isoforms. Ann. Rheum. Dis. 59:Suppl. 1 (2000), i60–64.
5. Banks, W.A., The blood-brain barrier in psychoneuroimmunology. Immunol. Allergy Clin. N. Am. 29:2 (2009), 223–228.
6. Banks, W.A., Kastin, A.J., Broadwell, R.D., Passage of cytokines across the blood-brain barrier. Neuroimmunomodulation 2:4 (1995), 241–248.
7. Banks, W.A., Plotkin, S.R., Kastin, A.J., Permeability of the blood-brain barrier to soluble cytokine receptors. Neuroimmunomodulation 2:3 (1995), 161–165.
8. Barbosa, I.G., Huguet, R.B., Mendonça, V.A., Sousa, L.P., Neves, F.S., Bauer, M.E., Teixeira, A.L., Increased plasma levels of soluble TNF receptor I in patients with bipolar disorder. Eur. Arch. Psychiatry Clin. Neurosci. 261 (2011), 139–143.
9. Benazzi, F., The relationship of major depressive disorder to bipolar disorder: continuous or discontinuous?. Curr. Psychiatry Rep. 7:6 (2005), 462–470.
10. Bengesser, S.A., Lackner, N., Birner, A., Fellendorf, F.T., Platzer, M., Mitteregger, A., Unterweger, R., Reininghaus, B., Mangge, H., Wallner-Liebmann, S.J., Zelzer, S., Fuchs, D., McIntyre, R.S., Kapfhammer, H.P., Reininghaus, E.Z., Peripheral markers of oxidative stress and antioxidative defense in euthymia of bipolar disorder–gender and obesity effects. J. Affect. Disord. 172 (2015), 367–374.
11. Berk, M., Kapczinski, F., Andreazza, A.C., Dean, O.M., Giorlando, F., Maes, M., Yücel, M., Gama, C.S., Dodd, S., Dean, B., Magalhães, P.V., Amminger, P., McGorry, P., Malhi, G.S., Pathways underlying neuroprogression in bipolar disorder: focus on inflammation, oxidative stress and neurotrophic factors. Neurosci. Biobehav. Rev. 35:3 (2011), 804–817.
12. Berk, M., Williams, L.J., Jacka, F.N., O'Neil, A., Pasco, J.A., Moylan, S., Allen, N.B., Stuart, A.L., Hayley, A.C., Byrne, M.L., Maes, M., So depression is an inflammatory disease, but where does the inflammation come from?. BMC Med., 11, 2013, 200.
13. Bilici, M., Efe, H., Köroğlu, M.A., Uydu, H.A., Bekaroğlu, M., Değer, O., Antioxidative enzyme activities and lipid peroxidation in major depression: alterations by antidepressant treatments. J. Affect. Disord. 64:1 (2011), 43–51.
14. Black, C., Miller, B.J., Meta-analysis of cytokines and chemokines in suicidality: distinguishing suicidal versus nonsuicidal patients. Biol. Psychiatry 78:1 (2015), 28–37.
15. Blanqué, R., Meakin, C., Millet, S., Gardner, C.R., Selective enhancement of LPS-induced serum TNF-alpha production by carrageenan pretreatment in mice. Gen. Pharmacol. 31:2 (1998), 301–306.
16. Bortolasci, C.C., Vargas, H.O., Souza-Nogueira, A., Barbosa, D.S., Moreira, E.G., Nunes, S.O., Berk, M., Dodd, S., Maes, M., Lowered plasma paraoxonase (PON)1 activity is a trait marker of major depression and PON1 Q192R gene polymorphism-smoking interactions differentially predict the odds of major depression and bipolar disorder. J. Affect. Disord. 159 (2014), 23–30.
17. Brown, N.C., Andreazza, A.C., Young, L.T., An updated meta-analysis of oxidative stress markers in bipolar disorder. Psychiatry Res. 218:1–2 (2014), 61–68.
18. Caruso, C., Candore, G., Cigna, D., Colucci, A.T., Modica, M.A., Biological significance of soluble IL-2 receptor. Mediat. Inflamm. 2:1 (1993), 3–21.
19. Celik, C., Erdem, M., Cayci, T., Ozdemir, B., Ozgur Akgul, E., Kurt, Y.G., Yaman, H., Isintas, M., Ozgen, F., Ozsahin, A., The association between serum levels of neopterin and number of depressive episodes of major depression. Prog. Neuro-Psychopharmacol. Biol. Psychiatry 34:2 (2010), 372–375.
20. Chang, B.P., Franklin, J.C., Ribeiro, J.D., Fox, K.R., Bentley, K.H., Kleiman, E.M., Nock, M.K., Biological risk factors for suicidal behaviors: a meta-analysis. Transl. Psychiatry, 6(9), 2016, e887.
21. Chowdhury, M.I., Hasan, M., Islam, M.S., Sarwar, M.S., Amin, M.N., Uddin, S.M., Rahaman, M.Z., Banik, S., Hussain, M.S., Yokota, K., Hasnat, A., Elevated serum MDA and depleted non-enzymatic antioxidants, macro-minerals and trace elements are associated with bipolar disorder. J. Trace Elem. Med. Biol. 39 (2017), 162–168.
22. Dinarello, C.A., A clinical perspective of IL-1β as the gatekeeper of inflammation. Eur. J. Immunol. 41 (2011), 1203–1217.
23. Dowlati, Y., Herrmann, N., Swardfager, W., Liu, H., Sham, L., Reim, E.K., Lanctôt, K.L., A meta-analysis of cytokines in major depression. Biol. Psychiatry 67 (2010), 446–457.
24. Ducasse, D., Olié, E., Guillaume, S., Artéro, S., Courtet, P., A meta-analysis of cytokines in suicidal behavior. Brain Behav. Immun. 46 (2015), 203–211.
25. Fiorentino, D.F., Zlotnik, A., Vieira, P., Mosmann, T.R., Howard, M., Moore, K.W., O'Garra, A., Pillars article: IL-10 acts on the antigen-presenting cell to inhibit cytokine production by Thl cells. J. Immunol. 1991. 146: 3444–3451. J. Immunol. 197:5 (2016), 1531–1538.
26. Goehler, L.E., Gaykema, R.P., Hansen, M.K., Anderson, K., Maier, S.F., Watkins, L.R., Vagal immune-to-brain communication: a visceral chemosensory pathway. Auton. Neurosci. 85:1–3 (2000), 49–59.
27. Goldsmith, D.R., Rapaport, M.H., Miller, B.J., A meta-analysis of blood cytokine network alterations in psychiatric patients: Comparisons between schizophrenia, bipolar disorder and depression. Mol. Psychiatry 21 (2016), 1696–1709.
28. Grassi-Oliveira, R., Brietzke, E., Pezzi, J.C., Lopes, R.P., Teixeira, A.L., Bauer, M.E., Increased soluble tumor necrosis factor-alpha receptors in patients with major depressive disorder. Psychiatry Clin. Neurosci. 63 (2009), 202–208.
29. Haapakoski, R., Mathieu, J., Ebmeier, K.P., Alenius, H., Kivimäki, M., Cumulative meta-analysis of interleukins 6 and 1β, tumour necrosis factor α and C-reactive protein in patients with major depressive disorder. Brain Behav. Immun. 49 (2015), 206–215.
30. Hamilton, M., A rating scale for depression. J. Neurol. Neurosurg. Psychiatry 23 (1960), 56–62.
31. Hiles, S.A., Baker, A.L., de Malmanche, T., Attia, J., A meta-analysis of differences in IL-6 and IL-10 between people with and without depression: exploring the causes of heterogeneity. Brain Behav. Immun. 26 (2012), 1180–1188.
32. Howren, M.B., Lamkin, D.M., Suls, J., Associations of depression with C-reactive protein, IL-1, and IL-6: a meta-analysis. Psychosom. Med. 71 (2009), 171–186.
33. Isung, J., Aeinehband, S., Mobarrez, F., Mårtensson, B., Nordström, P., Asberg, M., Piehl, F., Jokinen, J., Low vascular endothelial growth factor and interleukin-8 in cerebrospinal fluid of suicide attempters. Transl. Psychiatry, 20(2), 2012, e196.
34. Kanchanatawan, B., Sirivichayakul, S., Ruxrungtham, K., Carvalho, A.F., Geffard, M., Ormstad, H., Anderson, G., Maes, M., Deficit, but not nondeficit, schizophrenia is characterized by mucosa-associated activation of the tryptophan catabolite (TRYCAT) pathway with highly specific increases in IgA responses directed to picolinic, xanthurenic, and quinolinic acid. Mol. Neurobiol., 2017 2017 Feb 8 http://dx.doi.org/10.1007/s12035-017-0417-6 ([Epub Ahead of Print] PubMed PMID: 28181189).
35. Kay, J., Calabrese, L., The role of interleukin-1 in the pathogenesis of rheumatoid arthritis. Rheumatology (Oxford) 43:Suppl. 3 (2004), iii2–iii9.
36. Khanzode, S.D., Dakhale, G.N., Khanzode, S.S., Saoji, A., Palasodkar, R., Oxidative damage and major depression: the potential antioxidant action of selective serotonin re-uptake inhibitors. Redox Rep. 8:6 (2003), 365–370.
37. Kim, Y.K., Jung, H.G., Myint, A.M., Kim, H., Park, S.H., Imbalance between pro-inflammatory and anti-inflammatory cytokines in bipolar disorder. J. Affect. Disord. 104:1–3 (2007), 91–95.
38. Köhler, C.A., Freitas, T.H., Maes, M., de Andrade, N.Q., Liu, C.S., Fernandes, B.S., Stubbs, B., Solmi, M., Veronese, N., Herrmann, N., Raison, C.L., Miller, B.J., Lanctôt, K.L., Carvalho, A.F., Peripheral cytokine and chemokine alterations in depression: a meta-analysis of 82 studies. Acta Psychiatr. Scand., 2017 2017 Jan 25 http://dx.doi.org/10.1111/acps.12698 ([Epub ahead of print] PubMed PMID: 28122130).
39. Kunz, M., Gama, C.S., Andreazza, A.C., Salvador, M., Ceresér, K.M., Gomes, F.A., Belmonte-de-Abreu, P.S., Berk, M., Kapczinski, F., Elevated serum superoxide dismutase and thiobarbituric acid reactive substances in different phases of bipolar disorder and in schizophrenia. Prog. Neuro-Psychopharmacol. Biol. Psychiatry 32:7 (2008), 1677–1681.
40. Levine, J., Barak, Y., Chengappa, K.N., Rapoport, A., Rebey, M., Barak, V., Cerebrospinal cytokine levels in patients with acute depression. Neuropsychobiology 40:4 (1999), 171–176.
41. Liu, Y., Ho, R.C., Mak, A., Interleukin (IL)-6, tumour necrosis factor alpha (TNF-α) and soluble interleukin-2 receptors (sIL-2R) are elevated in patients with major depressive disorder: a meta-analysis and meta-regression. J. Affect. Disord. 139 (2012), 230–239.
42. Liu, T., Zhong, S., Liao, X., Chen, J., He, T., Lai, S., Jia, Y., A meta-analysis of oxidative stress markers in depression. PLoS One, 10(10), 2015, e0138904.
43. Machado-Vieira, R., Andreazza, A.C., Viale, C.I., Zanatto, V., Cereser, V. Jr., da Silva Vargas, R., Kapczinski, F., Portela, L.V., Souza, D.O., Salvador, M., Gentil, V., Oxidative stress parameters in unmedicated and treated bipolar subjects during initial manic episode: a possible role for lithium antioxidant effects. Neurosci. Lett. 421:1 (2007), 33–36.
44. Maes, M., Bosmans, E., Suy, E., Vandervorst, C., De Jonckheere, C., Raus, J., Immune disturbances during major depression: upregulated expression of interleukin-2 receptors. Neuropsychobiology 24 (1990), 115–120.
45. Maes, M., Bosmans, E., Suy, E., Vandervorst, C., DeJonckheere, C., Raus, J., Depression-related disturbances in mitogen-induced lymphocyte responses and interleukin-1 beta and soluble interleukin-2 receptor production. Acta Psychiatr. Scand. 84 (1991), 379–386.
46. Maes, M., Delanghe, J., Meltzer, H.Y., Scharpé, S., D'Hondt, P., Cosyns, P., Lower degree of esterification of serum cholesterol in depression: relevance for depression and suicide research. Acta Psychiatr. Scand. 90:4 (1994), 252–258.
47. Maes, M., Scharpé, S., Meltzer, H.Y., Okayli, G., Bosmans, E., D'Hondt, P., Vanden Bossche, B.V., Cosyns, P., Increased neopterin and interferon-gamma secretion and lower availability of L-tryptophan in major depression: further evidence for an immune response. Psychiatry Res. 54 (1994), 143–160.
48. Maes, M., Bosmans, E., Calabrese, J., Smith, R., Meltzer, H.Y., Interleukin-2 and interleukin-6 in schizophrenia and mania: effects of neuroleptics and mood stabilizers. J. Psychiatr. Res. 29:2 (1995), 141–152.
49. Maes, M., Meltzer, H.Y., Bosmans, E., Bergmans, R., Vandoolaeghe, E., Ranjan, R., Desnyder, R., Increased plasma concentrations of interleukin-6, soluble interleukin-6, soluble interleukin-2 and transferrin receptor in major depression. J. Affect. Disord. 34 (1995), 301–309.
50. Maes, M., Vandoolaeghe, E., Ranjan, R., Bosmans, E., Bergmans, R., Desnyder, R., Increased serum interleukin-1-receptor-antagonist concentrations in major depression. J. Affect. Disord. 36 (1995), 29–36.
51. Maes, M., Meltzer, H.Y, Buckley, P., Bosmans, E., Plasma-soluble interleukin-2 and transferrin receptor in schizophrenia and major depression. Eur. Arch. Psychiatry Clin. Neurosci. 244:6 (1995), 325–329.
52. Maes, M., Smith, R., Scharpe, S., The monocyte-T-lymphocyte hypothesis of major depression. Psychoneuroendocrinology 20:2 (1995), 111–116.
53. Maes, M., Bosmans, E., De Jongh, R., Kenis, G., Vandoolaeghe, E., Neels, H., Increased serum IL-6 and IL-1 receptor antagonist concentrations in major depression and treatment resistant depression. Cytokine 9 (1997), 853–858.
54. Maes, M., Delange, J., Ranjan, R., Meltzer, H.Y., Desnyder, R., Cooremans, W., Scharpé, S., Acute phase proteins in schizophrenia, mania and major depression: modulation by psychotropic drugs. Psychiatry Res. 66:1 (1997), 1–11.
55. Maes, M., Smith, R., Christophe, A., Vandoolaeghe, E., Van Gastel, A., Neels, H., Demedts, P., Wauters, A., Meltzer, H.Y., Lower serum high-density lipoprotein cholesterol (HDL-C) in major depression and in depressed men with serious suicidal attempts: relationship with immune-inflammatory markers. Acta Psychiatr. Scand. 95:3 (1997), 212–221.
56. Maes, M., Christophe, A., Delanghe, J., Altamura, C., Neels, H., Meltzer, H.Y., Lowered omega3 polyunsaturated fatty acids in serum phospholipids and cholesteryl esters of depressed patients. Psychiatry Res. 85:3 (1999), 275–291.
57. Maes, M., De Vos, N., Pioli, R., Demedts, P., Wauters, A., Neels, H., Christophe, A., Lower serum vitamin E concentrations in major depression. Another marker of lowered antioxidant defenses in that illness. J. Affect. Disord. 58:3 (2000), 241–246.
58. Maes, M., Ombelet, W., De Jongh, R., Kenis, G., Bosmans, E., The inflammatory response following delivery is amplified in women who previously suffered from major depression, suggesting that major depression is accompanied by a sensitization of the inflammatory response system. J. Affect. Disord. 63 (2001), 85–92.
59. Maes, M., Yirmyia, R., Noraberg, J., Brene, S., Hibbeln, J., Perini, G., Kubera, M., Bob, P., Lerer, B., Maj, M., The inflammatory & neurodegenerative (I&ND) hypothesis of depression: leads for future research and new drug developments in depression. Metab. Brain Dis. 24:1 (2009), 27–53.
60. Maes, M., Galecki, P., Chang, Y.S., Berk, M., A review on the oxidative and nitrosative stress (O&NS) pathways in major depression and their possible contribution to the (neuro)degenerative processes in that illness. Prog. Neuro-Psychopharmacol. Biol. Psychiatry 35 (2011), 676–692.
61. Maes, M., Berk, M., Goehler, L., Song, C., Anderson, G., Gałecki, P., Leonard, B., Depression and sickness behavior are Janus-faced responses to shared inflammatory pathways. BMC Med., 10, 2012, 66.
62. Maes, M., Mihaylova, I., Kubera, M., Ringel, K., Activation of cell-mediated immunity in depression: association with inflammation, melancholia, clinical staging and the fatigue and somatic symptom cluster of depression. Prog. Neuro-Psychopharmacol. Biol. Psychiatry 36:1 (2012), 169–175.
63. Maes, M., Song, C., Yirmiya, R., Targeting IL-1 in depression. Expert Opin. Ther. Targets 16:11 (2012), 1097–1112.
64. Maes, M., Kubera, M., Leunis, J.C., Berk, M., Geffard, M., Bosmans, E., In depression, bacterial translocation may drive inflammatory responses, oxidative and nitrosative stress (O&NS), and autoimmune responses directed against O&NS-damaged neoepitopes. Acta Psychiatr. Scand. 127:5 (2013), 344–354.
65. Maes, M., Kubera, M., Mihaylova, I., Geffard, M., Galecki, P., Leunis, J.C., Berk, M., Increased autoimmune responses against auto-epitopes modified by oxidative and nitrosative damage in depression: implications for the pathways to chronic depression and neuroprogression. J. Affect. Disord. 149:1–3 (2013), 23–29.
66. Maes, M., Anderson, G., Kubera, M., Berk, M., Targeting classical IL-6 signalling or IL-6 trans-signalling in depression?. Expert Opin. Ther. Targets 18 (2014), 495–512.
67. Mikova, O., Yakimova, R., Bosmans, E., Kenis, G., Maes, M., Increased serum tumor necrosis factor alpha concentrations in major depression and multiple sclerosis. Eur. Neuropsychopharmacol. 11 (2001), 203–208.
68. Modabbernia, A., Taslimi, S., Brietzke, E., Ashrafi, M., Cytokine alterations in bipolar disorder: a meta-analysis of 30 studies. Biol. Psychiatry 74:1 (2013), 15–25.
69. Monfrim, X., Gazal, M., De Leon, P.B., Quevedo, L., Souza, L.D., Jansen, K., Oses, J.P., Pinheiro, R.T., Silva, R.A., Lara, D.R., Ghisleni, G., Spessato, B., Kaster, M.P., Immune dysfunction in bipolar disorder and suicide risk: is there an association between peripheral corticotropin-releasing hormone and interleukin-1β?. Bipolar Disord. 16:7 (2014), 741–747.
70. Moreira, E.G., Correia, D.G., Bonifácio, K.L., Moraes, J.B., Cavicchioli, F.L., Nunes, C.S., Nunes, S.O.V., Vargas, H.O., Barbosa, D.S., Maes, M., Lowered PON1 activities are strongly associated with depression and bipolar disorder, recurrence of (hypo)mania and depression, increased disability and lowered quality of life. World J. Biol. Psychiatry. 30 (2017), 1–13.
71. Moreno, C., Hasin, D.S., Arango, C., Oquendo, M.A., Vieta, E., Liu, S., Grant, B.F., Blanco, C., Depression in bipolar disorder versus major depressive disorder: results from the National Epidemiologic Survey on Alcohol and Related Conditions. Bipolar Disord. 14:3 (2012), 271–282.
72. Moughrabi, S., Evangelista, L.S., Habib, S.I., Kassabian, L., Breen, E.C., Nyamathi, A., Irwin, M., In patients with stable heart failure, soluble TNF-receptor 2 is associated with increased risk for depressive symptoms. Biol. Res. Nurs. 16 (2014), 295–302.
73. Moylan, S., Berk, M., Dean, O.M., Samuni, Y., Williams, L.J., O'Neil, A., Hayley, A.C., Pasco, J.A., Anderson, G., Jacka, F.N., Maes, M., Oxidative & nitrosative stress in depression: why so much stress?. Neurosci. Biobehav. Rev. 45 (2014), 46–62.
74. Munkholm, K., Braüner, J.V., Kessing, L.V., Vinberg, M., Cytokines in bipolar disorder vs. healthy control subjects: a systematic review and meta-analysis. J. Psychiatr. Res. 47:9 (2013), 1119–1133.
75. Nunes, S.O., Piccoli de Melo, L.G., Pizzo de Castro, M.R., Barbosa, D.S., Vargas, H.O., Berk, M., Maes, M., Atherogenic index of plasma and atherogenic coefficient are increased in major depression and bipolar disorder, especially when comorbid with tobacco use disorder. J. Affect. Disord. 172 (2015), 55–62.
76. O'Brien, S.M., Scully, P., Scott, L.V., Dinan, T.G., Cytokine profiles in bipolar affective disorder: focus on acutely ill patients. J. Affect. Disord. 90:2–3 (2006), 263–267.
77. Ortiz-Domínguez, A., Hernández, M.E., Berlanga, C., Gutiérrez-Mora, D., Moreno, J., Heinze, G., Pavón, L., Immune variations in bipolar disorder: phasic differences. Bipolar Disord. 9:6 (2007), 596–602.
78. Ozcan, M.E., Gulec, M., Ozerol, E., Polat, R., Akyol, O., Antioxidant enzyme activities and oxidative stress in affective disorders. Int. Clin. Psychopharmacol. 19:2 (2004), 89–95.
79. Pandey, G.N., Ren, X., Rizavi, H.S., Zhang, H., Abnormal gene expression of proinflammatory cytokines and their receptors in the lymphocytes of patients with bipolar disorder. Bipolar Disord., 2015 2015, Aug 8 http://dx.doi.org/10.1111/bdi.12320 ([Epub ahead of print] PubMed PMID: 26257203).
80. Peet, M., Murphy, B., Shay, J., Horrobin, D., Depletion of omega-3 fatty acid levels in red blood cell membranes of depressive patients. Biol. Psychiatry 43:5 (1998), 315–319.
81. Perlis, R.H., Brown, E., Baker, R.W., Nierenberg, A.A., Clinical features of bipolar depression versus major depressive disorder in large multicenter trials. Am. J. Psychiatry 163:2 (2006), 225–231.
82. Perrier, S., Darakhshan, F., Hajduch, E., IL-1 receptor antagonist in metabolic diseases: Dr Jekyll or Mr Hyde?. FEBS Lett. 580 (2006), 6289–6294.
83. Prinz, M., Schmidt, H., Mildner, A., Knobeloch, K.P., Hanisch, U.K., Raasch, J., Merkler, D., Detje, C., Gutcher, I., Mages, J., Lang, R., Martin, R., Gold, R., Becher, B., Brück, W., Kalinke, U., Distinct and nonredundant in vivo functions of IFNAR on myeloid cells limit autoimmunity in the central nervous system. Immunity 28:5 (2008), 675–686.
84. Qu, J., Chen, W., Hu, R., Feng, H., The injury and therapy of reactive oxygen species in intracerebral hemorrhage looking at mitochondria. Oxidative Med. Cell. Longev., 2016, 2016, 2592935.
85. Ranjekar, P.K., Hinge, A., Hegde, M.V., Ghate, M., Kale, A., Sitasawad, S., Wagh, U.V., Debsikdar, V.B., Mahadik, S.P., Decreased antioxidant enzymes and membrane essential polyunsaturated fatty acids in schizophrenic and bipolar mood disorder patients. Psychiatry Res. 121:2 (2003), 109–122.
86. Rihmer, Z., Suicide risk in mood disorders. Curr. Opin. Psychiatry 20:1 (2007), 17–22.
87. Rizavi, H.S., Ren, X., Zhang, H., Bhaumik, R., Pandey, G.N., Abnormal gene expression of proinflammatory cytokines and their membrane-bound receptors in the lymphocytes of depressed patients. Psychiatry Res. 240 (2016), 314–320.
88. Rose-John, S., IL-6 trans-signaling via the soluble IL-6 receptor: importance for the pro-inflammatory activities of IL-6. Int. J. Biol. Sci. 8:9 (2012), 1237–1247.
89. Rudolf, S., Greggersen, W., Kahl, K.G., Hüppe, M., Schweiger, U., Elevated IL-6 levels in patients with atypical depression but not in patients with typical depression. Psychiatry Res. 217:1–2 (2014), 34–38.
90. Sarandol, A., Sarandol, E., Eker, S.S., Erdinc, S., Vatansever, E., Kirli, S., Major depressive disorder is accompanied with oxidative stress: short-term antidepressant treatment does not alter oxidative-antioxidative systems. Hum. Psychopharmacol. 22:2 (2007), 67–73.
91. Selinsky, C.L., Boroughs, K.L., Halsey, W.A. Jr., Howell, M.D., Multifaceted inhibition of anti-tumour immune mechanisms by soluble tumour necrosis factor receptor type I. Immunology 94 (1998), 88–93.
92. Shelton, R.C., Claiborne, J., Sidoryk-Wegrzynowicz, M., Reddy, R., Aschner, M., Lewis, D.A., Mirnics, K., Altered expression of genes involved in inflammation and apoptosis in frontal cortex in major depression. Mol. Psychiatry 16 (2011), 751–762.
93. Siwek, M., Sowa-Kućma, M., Styczeń, K., Misztak, P., Nowak, R.J., Szewczyk, B., Dudek, D., Rybakowski, J.K., Nowak, G., Maes, M., Associations of serum cytokine receptor levels with melancholia, staging of illness, depressive and manic phases, and severity of depression in bipolar disorder. Mol. Neurobiol., 2016 (2016 Sep 23. [Epub ahead of print] PubMed PMID: 27660275).
94. Siwek, M., Sowa-Kucma, M., Styczeń, K., Misztak, P., Szewczyk, B., Topor-Madry, R., Nowak, G., Dudek, D., Rybakowski, J.K., Thiobarbituric acid-reactive substances: markers of an acute episode and a late stage of bipolar disorder. Neuropsychobiology 73:2 (2016), 116–122.
95. Sobczak, S., Honig, A., Christophe, A., Maes, M., Helsdingen, R.W., De Vriese, S.A., Riedel, W.J., Lower high-density lipoprotein cholesterol and increased omega-6 polyunsaturated fatty acids in first-degree relatives of bipolar patients. Psychol. Med. 34:1 (2004), 103–112.
96. Sone, S., Orino, E., Mizuno, K., Yano, S., Nishioka, Y., Haku, T., Nii, A., Ogura, T., Production of IL-1 and its receptor antagonist is regulated differently by IFN-gamma and IL-4 in human monocytes and alveolar macrophages. Eur. Respir. J. 7 (1994), 657–663.
97. Sowa-Kucma M., Styczeń K., Siwek M, Misztak P, Nowak R.J., Dudek D., Rybakowski J.K., Nowak G. and Maes M., Lipid peroxidation and immune biomarkers are associated with major depression and its phenotypes, including treatment resistant depression and melancholia. (in progress).
98. Su, X., Zhou, T., Yang, P., Edwards, C.K. 3rd, Mountz, J.D., Reduction of arthritis and pneumonitis in motheaten mice by soluble tumor necrosis factor receptor. Arthritis Rheum. 41 (1998), 139–149.
99. Tsai, S.Y., Chung, K.H., Huang, S.H., Chen, P.H., Lee, H.C., Kuo, C.J., Persistent inflammation and its relationship to leptin and insulin in phases of bipolar disorder from acute depression to full remission. Bipolar Disord. 16:8 (2014), 800–808.
100. Tsuboi, H., Tatsumi, A., Yamamoto, K., Kobayashi, F., Shimoi, K., Kinae, N., Possible connections among job stress, depressive symptoms, lipid modulation and antioxidants. J. Affect. Disord. 91:1 (2006), 63–70.
101. Valkanova, V., Ebmeier, K.P., Allan, C.L., CRP, IL-6 and depression: a systematic review and meta-analysis of longitudinal studies. J. Affect. Disord. 150 (2013), 736–744.
102. Vargas, H.O., Nunes, S.O., Pizzo de Castro, M., Bortolasci, C.C., Sabbatini Barbosa, D., Kaminami Morimoto, H., Venugopal, K., Dodd, S., Maes, M., Berk, M., Oxidative stress and lowered total antioxidant status are associated with a history of suicide attempts. J. Affect. Disord. 150:3 (2013), 923–930.
103. Wadee, A.A., Kuschke, R.H., Wood, L.A., Berk, M., Ichim, L., Maes, M., Serological observations in patients suffering from acute manic episodes. Hum. Psychopharmacol. 17:4 (2002), 175–179.
104. Witkowska, A.M., On the role of sIL-2R measurements in rheumatoid arthritis and cancers. Mediat. Inflamm. 2005:3 (2005), 121–130.